Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab.
Autor: | Gori N; Dermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Chiricozzi A; Dermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Sfregola S; Section of Anatomic Pathology, Department of Life Sciences and Public Health, Sacred Heart Catholic University, Rome, Italy.; Unit of Anatomic Pathology, Department of Woman and Child Health and Public Health, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Ippoliti E; Dermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Di Stefani A; Dermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Malvaso D; Dermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Di Nardo L; Dermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy., Federico F; Section of Anatomic Pathology, Department of Life Sciences and Public Health, Sacred Heart Catholic University, Rome, Italy.; Unit of Anatomic Pathology, Department of Woman and Child Health and Public Health, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Zannoni GF; Section of Anatomic Pathology, Department of Life Sciences and Public Health, Sacred Heart Catholic University, Rome, Italy.; Unit of Anatomic Pathology, Department of Woman and Child Health and Public Health, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Peris K; Dermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy. |
---|---|
Jazyk: | angličtina |
Zdroj: | Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Dec 23; Vol. 50 (1), pp. 134-136. |
DOI: | 10.1093/ced/llae321 |
Abstrakt: | Over the past decade, dupilumab, a monoclonal human antibody that inhibits interleukin (IL)-4 and IL-13 signalling, has revolutionized the therapeutic management of moderate-to-severe atopic dermatitis (AD), facilitating long-term control of its signs and symptoms. The aim of this study was to identify histological predictors of the efficacy of dupilumab after 16 weeks of treatment in a cohort of 40 adults with moderate-to-severe AD who had undergone a skin biopsy for diagnostic purposes before treatment initiation. We found that Eczema Area and Severity Index (EASI) 75 and EASI 90 responses at week 16 were significantly associated with perivascular localization [odds ratio (OR) 17.6; P = 0.04] and lichenoid distribution (OR 31.8; P = 0.03) of the immune infiltrate. Moreover, for each unit increase in the number (cells mm-2) of CD4+ cells, the likelihood of achieving an EASI 75 response decreased by 1% (OR 0.99; P = 0.04). In conclusion, our study found promising pretreatment immunohistochemical markers that could predict how well patients with AD respond to dupilumab. Competing Interests: Conflicts of interest N.G. has served as an advisory board member and has received honoraria for lectures for AbbVie, Sanofi and LEO Pharma. A.C. has served as an advisory board member and consultant, and has received fees and speakers’ honoraria, or has participated in clinical trials for AbbVie, Almirall, Boehringer-Ingelheim, Bristol Myers Squibb, LEO Pharma, Lilly, Janssen, Novartis, Pfizer and Sanofi Genzyme. K.P. has served as an advisory board member and has received honoraria for lectures and/or research grants from AbbVie, Almirall, Lilly, Galderma, LEO Pharma, Pierre Fabre, Novartis, Sanofi, Sun Pharma and Janssen. The other authors report no conflict of interest. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.) |
Databáze: | MEDLINE |
Externí odkaz: |